【摘要】 目的 观察生脉散加减对慢性心力衰竭急性加重病人生长分化因子-15(GDF-15)、可溶性生长刺激表达基因2蛋白(sST2)水平的影响。方法 选取2019年4月—2020年5月在石家庄市中医院就诊的慢性心力衰竭急性加重病人250例，按照抽签法分为西医治疗组和生脉散加减治疗组，每组125例。西医治疗组给予贝那普利片治疗，生脉散加减治疗组给予生脉散加减治疗。酶联免疫吸附法检测GDF-15、sST2水平，心脏彩色多普勒超声仪检测左心室射血分数(LVEF)、心排血量(CO)、心脏指数(CI)、每搏量(SV)水平，化学发光法检测内皮素(ET)、醛固酮(ALD)、肾素活性(PRA)、血管紧张素Ⅱ(AngⅡ)水平，统计临床疗效并观察不良反应。结果 治疗后，两组GDF-15、sST2、ET、ALD、PRA、AngⅡ水平低于治疗前(P<0.05),LVEF、CO、CI、SV水平高于治疗前(P<0.05);治疗后，生脉散加减治疗组GDF-15、sST2、ET、ALD、PRA、AngⅡ水平低于西医治疗组(P<0.05),LVEF、CO、CI、SV水平高于西医治疗组(P<0.05),生脉散加减治疗组临床疗效总有效率高于西医治疗组(P<0.05),不良反应发生率低于西医治疗组(P<0.05)。结论 生脉散加减可有效缓解慢性心力衰竭急性加重病人的病情，改善GDF-15、sST2的水平，增强病人心功能。更多还原

【Abstract】 Objective To observe the effects of modified Shengmai Powder on growth differentiation factor-15(GDF-15) and soluble ST2(sST2)levels in chronic heart failure(CHF) patients with acute exacerbation.Methods A total of 250 patients with acute exacerbation of chronic heart failure admitted to Shijiazhuang Hospital of Traditional Chinese Medicine from April 2019 to May 2020 were selected and divided into western medicine group and modified Shengmai Powder group according to lottery method, with 125 patients in each group.Western medicine group was given benazepril tablet for treatment, modified Shengmai Powder group was given modified Shengmai Powder.GDF-15 and sST2 levels were detected by enzyme-linked immunosorbent assay, and left ventricular ejection fraction(LVEF),cardiac output(CO),cardiac index(CI),and stroke volume(SV)were detected by color Doppler echocardiography.Endothelin(ET),aldosterone(ALD),plasma renin activity(PRA),and angiotensin Ⅱ(AngⅡ) were detected by chemiluminescence.Clinical efficacy and adverse reactions were observed.Results After treatment, the levels of GDF-15,sST2,ET,ALD,PRA and Ang Ⅱ in both groups were lower than that before treatment(P<0.05),while the levels of LVEF,CO,CI,and SV were higher than that before treatment(P<0.05). The levels of GDF-15,sST2,ET,ALD,PRA and Ang Ⅱ in modified Shengmai Powder group were lower than those in the western medicine group(P<0.05),the levels of LVEF,CO,CI,and SV in modified Shengmai Powder group were higher than those in the western medicine group(P<0.05),and the total effective rate in modified Shengmai Powder group was higher than that in the western medicine group(P<0.05). The incidence of adverse reaction was lower than that in western medicine group(P< 0.05).Conclusion The modified Shengmai Powder can effectively relieve the condition of patients with acute exacerbation of chronic heart failure, improve the level of GDF-15 and sST2,and enhance the cardiac function of patients.更多还原